Kyowa Hakko Kirin Seeks Wider Use Of Dialysis Anemia Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's Kyowa Hakko Kirin applied to regulators to have its Nesp (darbepoetine) drug, now indicated for treating dialysis patients with renal anemia, also approved for cancer patients. Kyowa's application seeks approval for the drug in treating pre-dialysis patients and cancer patients who develop anemia following chemotherapy treatments. The company said it expects to get approval later this year and seesNesp as a successor to its Espo, which has a pre-dialysis indication. (Click here for more - a subscription may be required
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.